Cardio Diagnostics Holdings, Inc. (CDIO) is an AI-powered precision cardiovascular medicine company based in Chicago. Its core differentiation lies in combining genetics and epigenetics — the study of how environment and behavior alter gene expression — with machine learning to detect and assess coronary heart disease (CHD), a condition that remains the leading cause of death in the United States.
The company's flagship tests, Epi+Gen CHD (a three-year risk assessment) and PrecisionCHD (a detection and management tool), target a structural gap in cardiovascular care: PrecisionCHD can identify both obstructive and non-obstructive CHD, including forms that traditional angiograms may miss. This clinical differentiation supports the company's medium-term positioning in the growing preventive and precision-diagnostics segment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
From a competitive standpoint, CDIO operates at an early commercial stage. It holds an intellectual property portfolio spanning multiple major jurisdictions, which provides a defensible technology moat, but its small scale — a market capitalization in the single-digit millions — means the company must prove it can convert clinical differentiation into reimbursed, repeatable test volume. Expansion into employer groups, longevity clinics, telemedicine providers, and community organizations such as YMCAs reflects a deliberate effort to widen distribution without the heavy infrastructure costs of a traditional diagnostics rollout.
Several forward-looking developments could influence investor sentiment. The most consequential is Medicare reimbursement. The company has already obtained CPT codes for both tests and completed the "gap-fill" payment step, but coverage determination remains unresolved. A favorable coverage decision would lower a major adoption barrier for physicians and health systems, while a delay could prolong the company's cash-intensive commercialization phase.
International expansion into India, executed with Aimil Ltd. and Dr. Lal PathLabs — a network with more than 290 clinical laboratories — represents another important catalyst. With CHD rates in some Indian urban populations reaching roughly 13%, the partnership offers meaningful volume potential, though revenue is unlikely to materialize at scale until the commercial rollout accelerates later in 2026 and beyond.
Other catalysts include data presentations at medical conferences such as the American Heart Association Scientific Sessions, which can build clinical credibility; new community and provider partnerships; and the next quarterly earnings release, which will offer visibility into revenue momentum and cash runway. On the analyst front, coverage remains sparse and signals are mixed. Early coverage carried a notably high published price target, while a more recent Benchmark action maintained a Buy rating and revised its target to a lower level — illustrating how thin coverage can produce wide swings in consensus expectations as milestones are reassessed.
CDIO's trajectory is closely tied to broader healthcare and capital-market dynamics. Rising interest rates and tighter financing conditions disproportionately affect micro-cap, pre-profitability companies, influencing both the cost and availability of growth capital. Sustained commercialization may require additional fundraising, which in turn shapes dilution risk.
On the demand side, the secular rise of preventive medicine and value-based care favors diagnostics that shift treatment earlier in the disease cycle. An aging global population and the persistent burden of cardiovascular disease provide a durable tailwind. However, adoption depends heavily on reimbursement, clinical guideline inclusion, and physician willingness to order novel tests — regulatory and payer dynamics that can move slower than investor timelines. Geopolitical and supply-chain considerations are less direct for CDIO than for capital-intensive peers, but its India expansion does introduce foreign regulatory and operational variables.
Looking toward 2026 and beyond, Cardio Diagnostics' outlook hinges on converting its clinical differentiation into commercial scale. The India partnership and continued U.S. provider growth represent the clearest market-expansion levers, while Medicare coverage determination is the single most important regulatory variable for near-term adoption.
Long-term themes include the shift toward AI-enabled, blood-based cardiovascular screening, which could expand the company's addressable market if payer and clinical acceptance builds. Margin sustainability will depend on operating leverage as test volume grows, given the company's currently negative margins and modest revenue base. Capital allocation remains a central question: whether CDIO can reach sufficient scale before requiring further dilutive financing will be a defining test of its strategy.
Competitive threats include larger diagnostics players with greater distribution reach, as well as emerging AI-based cardiovascular screening competitors. Regulatory developments, particularly around reimbursement and clinical guideline integration, will continue to shape the pace of adoption. Because analyst coverage is thin, consensus expectations may remain volatile, and any published price targets should be viewed as external, point-in-time estimates rather than a forecast of the article's own.
In my own research, I often turn to Tickeron's Trend Prediction Engine when assessing micro-cap names like CDIO. This AI-driven tool provides forecasts on potential bullish, bearish, or sideways moves over the next week or month, along with historical context and alerts that help round out fundamental work.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The RSI Indicator for CDIO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 50 similar instances when the indicator left oversold territory. In 40 of the 50 cases the stock moved higher. This puts the odds of a move higher at 80%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CDIO as a result. In 41 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 25 of 38 cases over the following month. The odds of a continued upward trend are 66%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 48 of 139 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 23 of 36 cases where CDIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.
CDIO moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CDIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CDIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.586). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology